hotspot -WSS

hotspot

author：entertainment 2025-09-30 18:20:38 - browse：63

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Hospital at home shows how to bring innovation to health care

hotspot

WSS

Ukraine seeks to reclaim its role as a hub for clinical trials

Researchers tackle phage therapy hurdles for wider adoption

Hospital at home shows how to bring innovation to health care

Medicare Advantage enrollment hits roughly 33.4 million

Obamacare plans could cover weight loss drugs

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Wikipedia

hotspot

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

FDA advisory panel to debate high blood pressure devices

BioMarin wins approval for gene therapy to treat hemophilia A

A new drug could help frostbite victims avoid its ravages

Moonlake's readout produced a cash windfall. Risks remain

National associations that represent hospice owe an apology

Supreme Court strikes down use of affirmative action

Abortion policy in the spotlight at Republican debate

Hollywood unions extend contract negotiations for actors

CDC says it’s too soon to assess risk posed by Covid subvariant

leisure time

New CMS data security rules will hurt Medicare, Medicaid research

Hospital at home shows how to bring innovation to health care

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

FDA greenlights medical device to combat bladder issues

Former Pear Therapeutics executives start new VC firm

As AI regulations shape up, health tech startups beg for clarity

knowledge

hotspot

hotspot

hotspot